Skip Nav Destination
Issues
1 April 2012
-
Cover Image
Cover Image
The cover features a micropictogram (80X magnification) of H & E staining of a paraffin-embedded liver section of a mouse that received metformin to reduce or prevent hepatocellular carcinogenesis. Metformin (given as 250 mg/kg of body weight in chow) inhibited hepatocellular carcinogenesis induced by the liver-specific carcinogen diethylnitrosamine (DEN) in C57BL/6J mice. Mice injected with DEN at 2 weeks of age were put on metformin or control chow after weaning. At 24 or 36 weeks post-DEN treatment, livertumor multiplicity and size were reduced significantly in metformin-fed versus control-fed mice. Representative H & E sections indicate that the pathology of tumors in metformin-fed (featured on the cover) and controlfed mice (not shown) were similar, despite the decrease in tumor formation. In the cover image, the prominent oval shape at the bottom is a blood vessel in the portal tract (with additional vascular spaces below it). Just above and left of this vessel, a hepatocellular tumor appears as a circular cluster of larger cells with enlarged nuclei and somewhat more basophilic cytoplasm. See articles by Bhalla et al. (beginning on page 544) and by Pollak and Gonzalez-Angulo (beginning on page 500) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
From the Editor
Perspectives
Minireviews
Commentary
Research Articles
Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps
Matthew B. Yurgelun; Ajay Goel; Jason L. Hornick; Ananda Sen; Danielle Kim Turgeon; Mack T. Ruffin, IV; Norman E. Marcon; John A. Baron; Robert S. Bresalier; Sapna Syngal; Dean E. Brenner; C. Richard Boland; Elena M. Stoffel
A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients
Edward Messing; Jason R. Gee; Daniel R. Saltzstein; KyungMann Kim; Anthony diSant'Agnese; Jill Kolesar; Linda Harris; Adrienne Faerber; Thomas Havighurst; Jay M. Young; Mitchell Efros; Robert H. Getzenberg; Marcia A. Wheeler; Joseph Tangrea; Howard Parnes; Margaret House; J. Erik Busby; Raymond Hohl; Howard Bailey
Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade In Vitro and In Vivo
Peramaiyan Rajendran; Feng Li; Muthu K. Shanmugam; Radhamani Kannaiyan; Jen Nee Goh; Kwong Fai Wong; Wei Wang; Ester Khin; Vinay Tergaonkar; Alan Prem Kumar; John M. Luk; Gautam Sethi
Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
Jon J. Ladd; Tina Busald; Melissa M. Johnson; Qing Zhang; Sharon J. Pitteri; Hong Wang; Dean E. Brenner; Paul D. Lampe; Raju Kucherlapati; Ziding Feng; Ross L. Prentice; Samir M. Hanash
A Hexane Fraction of American Ginseng Suppresses Mouse Colitis and Associated Colon Cancer: Anti-inflammatory and Proapoptotic Mechanisms
Deepak Poudyal; Phuong Mai Le; Tia Davis; Anne B. Hofseth; Alena Chumanevich; Alexander A. Chumanevich; Michael J. Wargovich; Mitzi Nagarkatti; Prakash S. Nagarkatti; Anthony Windust; Lorne J. Hofseth
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.